# FEB 1 2 2009

# 510(k) Summary

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, address, contact

Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250 317-521-3208

Contact Person: Kelly French

Date Prepared: November 20, 2008

# Device Name

Proprietary name: Elecsys Toxo IgG CalCheck

Common name: Toxo IgG CalCheck

Classification name: Single (specified) analyte controls (assayed and unassayed)

# Predicate device

The Elecsys Toxo IgG CalCheck is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalency to the currently marketed Elccsys C-Peptide CalCheck (K040157).

Device Description

The Elecsys Toxo IgG CalCheck is a lyophilized product consisting of human anti-Toxo IgG antibodies in human serum matrix. During manufacture, the analytes are spiked into the matrix at the desired concentration levels.

# Intended use

For use in the verification of the calibration established by the Elecsys Toxo IgG reagent on the Elecsys and cobas e immunoassay analyzers.

Continued on next page

The table below compares Elecsys Toxo IgG CalCheck with the predicate device, Elecsys C-Peptide Calcheck (K040157).

Comparison Table   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys C- Peptide CalCheck(K040157)</td><td rowspan=1 colspan=1>Elecsys Toxo IgG CalCheck</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For use in the verification of thecalibration established by theElecsys C-Peptide reagent on theElecsys and cobas e immunoassayanalyzers.</td><td rowspan=1 colspan=1>For use in the verification of thecalibration established by the ElecsysToxo IgG reagent on the Elecsys andcobas e immunoassay analyzers.</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Three</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Reconstitute with exactly 1.0 mLdistilled or deionized water andallow standing closed for 15minutes, then mixing gently.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Store at 2-8Â°C until expirationdateReconstituted:20 - 25 C : 4 hrs</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>equine serum matrix</td><td rowspan=1 colspan=1>Human serum</td></tr></table>

# Performance Characteristics

The Elecsys Toxo IgG CalCheck was cvaluated for value assignment and stability.

# FEB 1 2 2009

Ms. Kelly French   
Regulatory Affairs Consultant   
Roche Diagnostics   
9115 Hague Road   
Indianapolis, IN 46250-3831

Re: K083655 Trade/Device Name: Elecsys Toxo IgG CalCheck Regulation Number: 21 CFR 862.1660 21 CFR 866.3780 Regulation Name: Quality control material (assayed and unassayed) Toxoplasma gondii serological reagents Regulatory Class: I, II Product Code: JJX, LGD Dated: December 9, 2008 Received: December 10, 2008

Dear Ms. French:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter willallow you to begin marketing your device as described in your Section $5 1 0 ( \mathrm { k } )$ premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address htp://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

![](images/4ef4e724e29c18fce85111f2fc9d1f550c15d0611ef5f35472f1118159e33b8e.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indication for Use

510(k) Number (if known): K083653

Device Name: Elecsys Toxo IgG CalCheck

Indication For Use:

The Elecsys Toxo IgG CalCheck, as assayed calibrator control, is intended for use in the verification of the calibration established by the Elecsys Toxo IgG reagent on the Elecsys 2010, the MODULAR ANALYTICS E170, and cobas e immunoassay analyzers.